الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 173 |  |  |
| | | from | 173 | | |
Abstract
This prospective study was conducted at tertiary care hospital at the breast surgery unit and clinical oncology departments, Ain Shams University Hospitals from 2015 till 2017 and performed on a total of 60 female patients with newly diagnosed early breast cancer patients according to TNM staging system.
During the follow-up of the patients, the current study results revealed that Ki-67 was significantly decreased with significantly decreased tumor size at follow up among the studied cases.
As regards the clinical response after neoadjuvant chemotherapy, the current study results revealed that Partial response was the most frequent among the studied cases with no statistically significant differences according to clinical response regarding age, hormone status and baseline tumor size.
Baseline and follow up Ki-67 were lowest in complete response, followed by partial response, then stable disease and highest in progressive response, the differences statistically were significant.
Consequently, change percent of Ki-67 were highest in complete response, followed by partial response, then stable disease and lowest in progressive response, the differences statistically were significant. Ki-67 significantly decreased in complete response, partial response and stable disease and non-significantly changed in progressive response.
As a result, Ki-67 statistically had significant moderate diagnostic performance in predicting clinical responses, was highest in predicting progressive response.
We concluded that Ki-67 is a valuable marker, as it has prognostic and predictive abilities after neoadjuvant chemotherapy. Ki-67 expression may be considered a valuable potential biomarker and add a prognostic information to that obtained from classical prognostic factors such as tumor size.